Gothenburg, Sweden March 22, 2021 – Elicera Therapeutics, a cell- and gene therapy company in clinical phase, developing immuno-oncology treatments with a focus on CAR T-cells and oncolytic viruses, today announced that Karin Hoogendoorn (PharmD) has been appointed to the Board. She joins as a key cell therapy expert when Elicera plans an IPO in Q2, 2020. The Company works for an accelerated development of Elicera’s next generation oncolytic virus and CAR T-cell clinical and pre-clinical programs, together with its proprietary iTANK platform for optimizing CAR T-cells.
Hoogendoon has 25 years of experience in the pharmaceutical industry, predominantly in the field of advanced therapy medicinal products (ATMPs), monoclonal antibodies and viral vector based vaccines. She has held various roles of increasing responsibility covering chemical, manufacturing and controls (CMC) and regulatory affairs from pre-clinical to commercial phases for small, medium and large pharmaceutical companies in the Netherlands, Switzerland, Sweden and Japan. Currently, she is a member of the International Advisory Board of the Swedish Centre for Advanced Medical Products (CAMP).
“I am delighted to join Elicera at this exciting time for both the company as for cell and gene therapy in general,’ says Hoogendoon. ‘Elicera’s pipeline of oncolytic virus and CAR-T cell drug candidates has the potential to significantly improve the efficacy of combination therapies, while I believe iTANK represents a major breakthrough with its ability to broaden CD8+ T-cell activation. ”
“The clinical development of Cell and gene therapy is a highly complex field and we are delighted to welcome Karin to the Board and start to benefit from her knowhow and experience,” comments Jamal El-Mosleh, CEO Elicera. “She joins as we look to advance our clinical programs where we believe our candidates offer both next generation advantages and synergies for combination use.”
About Elicera Therapeutics
Elicera is a clinical stage cell and gene therapy company active in the field of immuno-oncology. Based on the leading research by Professor Magnus Essand’s work at Uppsala University, the Company has four drug candidates, two in the field of CAR-T cells and two in the field of oncolytic viruses. Most advanced is ELC-100, an oncolytic virus for NET which is Phase I/II, while ELC-301, an enhanced CAR-T
therapy is due to enter Phase I second half of 2022. Elicera has also completed development of a proprietary technology platform called iTANK (immunoTherapies Activated with NAP for efficient Killing) for optimization of any CAR T-cell therapy under development and generation of a second mode of action through activation of CD8+ T-cells against cancer.
For more information, please visit www.elicera.com
Jamal El-Mosleh, CEO
Tel: +46703319051 firstname.lastname@example.org
Nordics -Ola Bjorkman, Let’em know Tel: +46 70 245 74 97 Ola.email@example.com
International -Richard Hayhurst, RHApr
Tel: +44 (0) 7711 821 527